Labcorp Holdings annual return on equity
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Labcorp Holdings Return on Equity (ROE) Growth & History (LH)
Labcorp Holdings's return on equity was 10.51% for fiscal 2025.
View full Labcorp Holdings company overviewLabcorp Holdings annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 10.51% | +1.15 pp |
| 2024 | 2024-12-31 | 9.37% | +4.72 pp |
| 2023 | 2023-12-31 | 4.65% | −7.91 pp |
| 2022 | 2022-12-31 | 12.56% | −11.56 pp |
| 2021 | 2021-12-31 | 24.12% | +5.90 pp |
| 2020 | 2020-12-31 | 18.22% | +7.01 pp |
| 2019 | 2019-12-31 | 11.21% | −1.54 pp |
| 2018 | 2018-12-31 | 12.76% | −7.16 pp |
| 2017 | 2017-12-31 | 19.92% | +6.31 pp |
| 2016 | 2016-12-31 | 13.61% | +2.34 pp |
| 2015 | 2015-12-31 | 11.27% | −7.98 pp |
| 2014 | 2014-12-31 | 19.25% | +3.82 pp |
| 2013 | 2013-12-31 | 15.43% | −0.22 pp |
| 2012 | 2012-12-31 | 15.66% | −5.26 pp |
| 2011 | 2011-12-31 | 20.91% | −3.50 pp |
| 2010 | 2010-12-31 | 24.42% | −4.22 pp |
| 2009 | 2009-12-31 | 28.64% | +1.42 pp |
| 2008 | 2008-12-31 | 27.21% | — |
Labcorp Holdings quarterly return on equity
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.45% | +0.61 pp |
| Q1 2026 | 2026-03-31 | 3.20% | +0.60 pp |
| Q4 2025 | 2025-12-31 | 1.90% | +0.13 pp |
| Q3 2025 | 2025-09-30 | 3.04% | +0.95 pp |
| Q2 2025 | 2025-06-30 | 2.84% | +0.26 pp |
| Q1 2025 | 2025-03-31 | 2.60% | −0.28 pp |
| Q4 2024 | 2024-12-31 | 1.77% | +3.89 pp |
| Q3 2024 | 2024-09-30 | 2.09% | −0.11 pp |
| Q2 2024 | 2024-06-30 | 2.57% | +0.42 pp |
| Q1 2024 | 2024-03-31 | 2.88% | +0.62 pp |
| Q4 2023 | 2023-12-31 | −2.12% | −2.88 pp |
| Q3 2023 | 2023-09-30 | 2.20% | −1.24 pp |
| Q2 2023 | 2023-06-30 | 2.15% | −1.25 pp |
| Q1 2023 | 2023-03-31 | 2.26% | −2.43 pp |
| Q4 2022 | 2022-12-31 | 0.75% | −4.54 pp |
| Q3 2022 | 2022-09-30 | 3.44% | −2.17 pp |
| Q2 2022 | 2022-06-30 | 3.40% | −1.20 pp |
| Q1 2022 | 2022-03-31 | 4.68% | −3.23 pp |
| Q4 2021 | 2021-12-31 | 5.30% | −5.32 pp |
| Q3 2021 | 2021-09-30 | 5.61% | −3.41 pp |
| Q2 2021 | 2021-06-30 | 4.60% | +1.37 pp |
| Q1 2021 | 2021-03-31 | 7.91% | +12.24 pp |
| Q4 2020 | 2020-12-31 | 10.62% | +7.56 pp |
| Q3 2020 | 2020-09-30 | 9.02% | +13.44 pp |
| Q2 2020 | 2020-06-30 | 3.22% | +0.55 pp |
| Q1 2020 | 2020-03-31 | −4.33% | −6.95 pp |
| Q4 2019 | 2019-12-31 | 3.05% | +0.84 pp |
| Q3 2019 | 2019-09-30 | −4.41% | −8.88 pp |
| Q2 2019 | 2019-06-30 | 2.67% | −0.66 pp |
| Q1 2019 | 2019-03-31 | 2.62% | +0.11 pp |
| Q4 2018 | 2018-12-31 | 2.21% | −8.44 pp |
| Q3 2018 | 2018-09-30 | 4.46% | +1.60 pp |
| Q2 2018 | 2018-06-30 | 3.33% | +0.13 pp |
| Q1 2018 | 2018-03-31 | 2.51% | −0.76 pp |
| Q4 2017 | 2017-12-31 | 10.64% | +7.33 pp |
| Q3 2017 | 2017-09-30 | 2.86% | −0.43 pp |
| Q2 2017 | 2017-06-30 | 3.21% | −0.69 pp |
| Q1 2017 | 2017-03-31 | 3.28% | +0.03 pp |
| Q4 2016 | 2016-12-31 | 3.32% | +1.06 pp |
| Q3 2016 | 2016-09-30 | 3.29% | +0.06 pp |
| Q2 2016 | 2016-06-30 | 3.90% | +0.19 pp |
| Q1 2016 | 2016-03-31 | 3.25% | +3.16 pp |
| Q4 2015 | 2015-12-31 | 2.26% | −2.02 pp |
| Q3 2015 | 2015-09-30 | 3.23% | −1.82 pp |
| Q2 2015 | 2015-06-30 | 3.71% | −1.77 pp |
| Q1 2015 | 2015-03-31 | 0.08% | −20.40 pp |
| Q4 2014 | 2014-12-31 | 4.28% | −0.72 pp |
| Q3 2014 | 2014-09-30 | 5.06% | −0.62 pp |
| Q2 2014 | 2014-06-30 | 5.48% | −0.10 pp |
| Q1 2014 | 2014-03-31 | 20.48% | +16.67 pp |
| Q4 2013 | 2013-12-31 | 5.00% | +1.86 pp |
| Q3 2013 | 2013-09-30 | 5.67% | +0.14 pp |
| Q2 2013 | 2013-06-30 | 5.58% | −0.28 pp |
| Q1 2013 | 2013-03-31 | 3.81% | −2.52 pp |
| Q4 2012 | 2012-12-31 | 3.14% | −2.23 pp |
| Q3 2012 | 2012-09-30 | 5.53% | +0.29 pp |
| Q2 2012 | 2012-06-30 | 5.86% | +0.93 pp |
| Q1 2012 | 2012-03-31 | 6.34% | +1.11 pp |
| Q4 2011 | 2011-12-31 | 5.37% | −0.20 pp |
| Q3 2011 | 2011-09-30 | 5.24% | −1.01 pp |
| Q2 2011 | 2011-06-30 | 4.94% | −2.10 pp |
| Q1 2011 | 2011-03-31 | 5.22% | −1.00 pp |
| Q4 2010 | 2010-12-31 | 5.57% | −1.34 pp |
| Q3 2010 | 2010-09-30 | 6.25% | −0.26 pp |
| Q2 2010 | 2010-06-30 | 7.04% | −0.34 pp |
| Q1 2010 | 2010-03-31 | 6.22% | — |
| Q4 2009 | 2009-12-31 | 6.90% | — |
| Q3 2009 | 2009-09-30 | 6.51% | — |
| Q2 2009 | 2009-06-30 | 7.38% | — |
Labcorp Holdings return on equity trends
Over the last five fiscal years, Labcorp Holdings's return on equity decreased from 18.22% to 10.51%, a change of −7.71 percentage points. The latest reported quarter, Q2 2026, shows 3.45%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Labcorp Holdings source filings ↗Community posts
Labcorp sets new medium-term growth targets and reaffirms its annual outlook
Labcorp ($LH) set medium-term targets for annual revenue growth of 5–8% and adjusted earnings-per-share growth of 8.5–11.5% through 2029. The company also reaffirmed its existing 2026 guidance. The new framework describes the performance ma ...
Labcorp acquires MLM Medical Labs to expand clinical-trial services
Labcorp ($LH) acquired MLM Medical Labs, adding central and specialty laboratory operations in the United States, Germany and South Africa. The company said the purchase expands its biomarker-testing capabilities and improves its ability to ...